Selonsertib has been investigated primarily for its potential in treating chronic liver diseases, particularly those involving apoptosis and inflammation pathways. It functions as an ASK1 (apoptosis signal-regulating kinase 1) inhibitor, which plays a key role in stress-induced apoptosis and inflammatory signaling. By inhibiting ASK1, Selonsertib helps reduce hepatocyte cell death and inflammation, making it a candidate for conditions such as non-alcoholic steatohepatitis (NASH) and liver fibrosis. Clinical trials have evaluated its efficacy in slowing fibrosis progression and improving liver histology in patients with NASH. It has also been studied in combination with other agents targeting metabolic and fibrotic pathways to enhance therapeutic outcomes. Additionally, research has explored its use in other conditions where oxidative stress and inflammation contribute to disease progression, including certain neurodegenerative and cardiovascular disorders, though liver-related applications remain the primary focus.